-
1.发明授权Nucleic acids encoding DNA structure-specific recognition protein and uses therefor 失效编码DNA结构特异性识别蛋白的核酸及其用途
公开(公告)号：US5359047A
公开(公告)日：1994-10-25
申请号：US814964
申请日：1991-12-26
申请人： Brian A. Donahue , Jeffrey H. Toney , John M. Essigmann , Stephen J. Lippard , Pieter M. Pil , Suzanne L. Bruhn , Steven J. Brown , Patti J. Kellett
发明人： Brian A. Donahue , Jeffrey H. Toney , John M. Essigmann , Stephen J. Lippard , Pieter M. Pil , Suzanne L. Bruhn , Steven J. Brown , Patti J. Kellett
IPC分类号： C12N15/09 , A61K38/00 , C07K14/39 , C07K14/435 , C07K14/47 , C07K16/00 , C07K16/18 , C12P21/02 , C12P21/08 , C12Q1/68 , C17N5/12
CPC分类号： C07K14/47 , C07K14/435 , C07K14/43581 , C07K16/18 , C12Q1/6876 , C12Q1/6883 , A61K38/00 , C12Q2600/142 , C12Q2600/158
摘要： DNA structure specific recognition protein of eukaryotic origin and DNA encoding such a factor, as well as probes specific for DNA structure specific recognition protein or DNA encoding it and methods of detecting DNA structure specific recognition protein in eukaryotic cells. In particular, a mammalian cellular factor that selectively recognizes and binds DNA damaged or modified by a drug (the anticancer drug, cis-diamminedichloroplatinum (II) or cisplatin) has been identified.
摘要翻译： 真核生物的DNA结构特异性识别蛋白和编码这样一个因子的DNA，以及DNA结构特异性识别蛋白或编码DNA的探针，以及检测真核细胞中DNA结构特异性识别蛋白的方法。 特别地，已经鉴定了选择性识别和结合被药物（抗癌药物，顺式二氨基二氯铂（II）或顺铂）损伤或修饰的DNA的哺乳动物细胞因子。
-
公开(公告)号：US5670621A
公开(公告)日：1997-09-23
申请号：US258442
申请日：1994-06-09
申请人： Brian A. Donahue , Jeffrey H. Toney , John M. Essigmann , Stephen J. Lippard , Pieter M. Pil , Suzanne L. Bruhn , Steven J. Brown , Patti J. Kellett
发明人： Brian A. Donahue , Jeffrey H. Toney , John M. Essigmann , Stephen J. Lippard , Pieter M. Pil , Suzanne L. Bruhn , Steven J. Brown , Patti J. Kellett
IPC分类号： C12N15/09 , A61K38/00 , C07K14/39 , C07K14/435 , C07K14/47 , C07K16/00 , C07K16/18 , C12P21/02 , C12P21/08 , C12Q1/68 , C12N15/11
CPC分类号： C07K14/47 , C07K14/435 , C07K14/43581 , C07K16/18 , C12Q1/6876 , C12Q1/6883 , A61K38/00 , C12Q2600/142 , C12Q2600/158
摘要： DNA structure specific recognition protein of eukaryotic origin and DNA encoding such a factor, as well as probes specific for DNA structure specific recognition protein or DNA encoding it and methods of detecting DNA structure specific recognition protein in eukaryotic cells. In particular, a mammalian cellular factor that selectively recognizes and binds DNA damaged or modified by a drug (the anticancer drug, cis-diamminedichloroplatinum (II) or cisplatin) has been identified.
摘要翻译： 真核生物的DNA结构特异性识别蛋白和编码这样一个因子的DNA，以及DNA结构特异性识别蛋白或编码DNA的探针，以及检测真核细胞中DNA结构特异性识别蛋白的方法。 特别地，已经鉴定了选择性识别和结合被药物（抗癌药物，顺式二氨基二氯铂（II）或顺铂）损伤或修饰的DNA的哺乳动物细胞因子。
-
公开(公告)号：US06475791B1
公开(公告)日：2002-11-05
申请号：US08866840
申请日：1997-06-02
申请人： Stephen J. Lippard , John M. Essigmann , Brian A. Donahue , Jeffrey H. Toney , Suzanne L. Bruhn , Pieter M. Pil , Steven J. Brown , Patti J. Kellett
发明人： Stephen J. Lippard , John M. Essigmann , Brian A. Donahue , Jeffrey H. Toney , Suzanne L. Bruhn , Pieter M. Pil , Steven J. Brown , Patti J. Kellett
IPC分类号： A61K4800
CPC分类号： C07K14/435 , A61K38/00 , C07K14/43581 , C07K14/47 , C07K16/18 , C12Q1/68 , C12Q1/6876 , C12Q1/6883 , C12Q2600/142
摘要： Methods disclosed herein capitalize on the ability of DNA Structure Specific Recognition Proteins (SSRPs) to bind to genomic lesions formed by chemotherapeutic agents, particularly cisplatin-type agents. Methods are provided for predicting whether an agent that damages DNA will also be cytotoxic, and for predicting whether particular eukaryotic cells will be susceptible to killing by a genotoxic drug. A screening method is provided for identifying new genotoxic drugs that produce SSRP-recognized lesions in DNA. Methods also are provided for sensitizing particular eukaryotic cells to killing by chemotherapeutic agents, particularly cisplatin-type drugs.
摘要翻译： 本文公开的方法利用DNA结构特异性识别蛋白（SSRP）结合由化学治疗剂，特别是顺铂型药剂形成的基因组病变的能力。 提供了用于预测损害DNA的药物是否也将是细胞毒性的方法，以及用于预测特定真核细胞是否易于被遗传毒性药物杀死的方法。 提供了一种筛选方法，用于鉴定在DNA中产生SSRP识别的病变的新基因毒性药物。 提供了用于使特定真核细胞对化学治疗剂，特别是顺铂类药物杀死的方法。
-
公开(公告)号：US5705334A
公开(公告)日：1998-01-06
申请号：US328809
申请日：1994-10-25
申请人： Stephen J. Lippard , John M. Essigmann , Brian Donahue , Jeffrey H. Toney , Suzanne L. Bruhn , Pieter M. Pil , Steven J. Brown , Patti J. Kellett
发明人： Stephen J. Lippard , John M. Essigmann , Brian Donahue , Jeffrey H. Toney , Suzanne L. Bruhn , Pieter M. Pil , Steven J. Brown , Patti J. Kellett
CPC分类号： C07K14/435 , C07K14/43581 , C07K14/47 , C07K16/18 , C12Q1/68 , C12Q1/6876 , C12Q1/6883 , A61K38/00 , C12Q2600/142
摘要： Methods disclosed herein capitalize on the ability of DNA Structure Specific Recognition Proteins (SSRPs) to bind to genomic lesions formed by chemotherapeutic agents, particularly cisplatin-type agents. Methods are provided for predicting whether an agent that damages DNA will also be cytotoxic, and for predicting whether particular eukaryotic cells will be susceptible to killing by a genotoxic drug. A screening method is provided for identifying new genotoxic drugs that produce SSRP-recognized lesions in DNA. Methods also are provided for sensitizing particular eukaryotic cells to killing by chemotherapeutic agents, particularly cisplatin-type drugs.
-
公开(公告)号：US09265747B2
公开(公告)日：2016-02-23
申请号：US13060354
申请日：2009-08-26
申请人： Stephen J. Lippard , Shanta Dhar
发明人： Stephen J. Lippard , Shanta Dhar
IPC分类号： A61K31/282 , A61K31/19 , A61K33/24 , A61K45/06
CPC分类号： A61K31/282 , A61K31/19 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects in need of therapeutic protocol, including subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a first component comprising a precursor to a therapeutically active platinum agent and a precursor to a second therapeutically active agent. The therapeutically active platinum agent and the second therapeutically active agent may dissociate from each other, thereby forming a first therapeutically active platinum agent and a second therapeutically active agent. The second therapeutically active gent may affect a cellular pathway of a cancer cell and may be substantially inactive towards non-cancerous cells.
摘要翻译： 本发明提供了可用于治疗需要治疗方案的受治疗者的组合物，制剂，制剂，试剂盒和方法，包括具有癌症或有发展癌症风险的受试者。 本发明的一些实施方案可以包含包含第一组分的组合物，所述第一组分包含治疗活性铂剂的前体和第二治疗活性剂的前体。 治疗活性的铂剂和第二治疗活性剂可以彼此解离，从而形成第一治疗活性的铂剂和第二治疗活性剂。 第二治疗活性配偶可能影响癌细胞的细胞途径，并且可能对非癌细胞基本上无活性。
-
公开(公告)号：US08603532B2
公开(公告)日：2013-12-10
申请号：US13122615
申请日：2009-10-20
CPC分类号： A61K9/48 , A61K9/143 , A61K31/555 , A61K33/24 , A61K47/48092 , A61K47/48869 , A61K47/48915 , A61K47/549 , A61K47/6925 , A61K47/6937 , B82Y5/00
摘要： The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.
摘要翻译： 本发明提供了可用于治疗患有癌症或有癌症发生危险的受试者的组合物，制剂，制剂，试剂盒和方法。 本发明的一些实施方案可以包含包含多个包含铂（IV）治疗活性前体的颗粒的组合物。
-
公开(公告)号：US20130029959A1
公开(公告)日：2013-01-31
申请号：US13529965
申请日：2012-06-21
申请人： Stephen J. Lippard , Ga Young Park
发明人： Stephen J. Lippard , Ga Young Park
IPC分类号： A61K31/555 , A61P35/00 , C07F15/00
CPC分类号： C07F15/0093
摘要： The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand.
摘要翻译： 本发明涉及用于治疗癌症的组合物，试剂盒和方法。 在一些情况下，组合物包含含有菲啶配体的铂化合物。
-
8.发明申请POLYVALENT POLYNUCLEOTIDE NANOPARTICLE CONJUGATES AS DELIVERY VEHICLES FOR A CHEMOTHERAPEUTIC AGENT 审中-公开多价多核苷酸纳米粒子作为化学药剂的交付车辆公开(公告)号：US20120244230A1
公开(公告)日：2012-09-27
申请号：US13393454
申请日：2010-09-01
CPC分类号： B82Y5/00 , A61K47/6923
摘要： The present invention is directed to compositions and methods of delivering a chemotherapeutic agent via a polynueleotide-functionalized nanoparticle (PN-NP).
摘要翻译： 本发明涉及通过多核苷酸官能化的纳米颗粒（PN-NP）递送化学治疗剂的组合物和方法。
-
公开(公告)号：US20120164230A1
公开(公告)日：2012-06-28
申请号：US12115709
申请日：2008-05-06
CPC分类号： A61K31/282 , B82Y5/00 , C07F15/0093 , C08B37/0021
摘要： Compounds and methods are disclosed in which a prodrug can be delivered in an elevated oxidative state to cells by means of graphitic nanoparticles to which the prodrug is attached by a hydrophilic polymer and which have been made soluble by a hydrophilic polymer, such as PEG. The graphitic nanoparticle may be a single walled carbon nanotube (SWNT). The prodrug may be a DNA-binding metal-based drug. Exemplified is a platinum(IV) complex c,c,t-[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)], which is nearly nontoxic to testicular cancer cells, but displays a significantly enhanced cytotoxicity profile when attached to the surface of amine-functionalized soluble SWNTs. An amine functionality on the hydrophilic polymer may be used to link the prodrug.
摘要翻译： 公开了化合物和方法，其中前药可以通过石墨纳米颗粒以升高的氧化态递送至前体药物通过亲水性聚合物连接并且已经通过亲水性聚合物如PEG所溶解。 石墨纳米颗粒可以是单壁碳纳米管（SWNT）。 前药可以是基于DNA结合金属的药物。 示例是铂（IV）络合物c，c，t- [Pt（NH 3）2 Cl 2（OEt）（O 2 CCH 2 CH 2 CO 2 H）]，其对睾丸癌细胞几乎无毒，但当附着于睾丸癌细胞表面时显示出显着增强的细胞毒性特征 胺官能化的可溶性SWNT。 亲水性聚合物上的胺官能团可用于连接前体药物。
-
公开(公告)号：US20110300219A1
公开(公告)日：2011-12-08
申请号：US13122615
申请日：2009-10-20
IPC分类号： A61K9/14 , A61P35/00 , A61K39/00 , A61K33/00 , A61K31/282
CPC分类号： A61K9/48 , A61K9/143 , A61K31/555 , A61K33/24 , A61K47/48092 , A61K47/48869 , A61K47/48915 , A61K47/549 , A61K47/6925 , A61K47/6937 , B82Y5/00
摘要： The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.
摘要翻译： 本发明提供了可用于治疗患有癌症或有癌症发生危险的受试者的组合物，制剂，制剂，试剂盒和方法。 本发明的一些实施方案可以包含包含多个包含铂（IV）治疗活性前体的颗粒的组合物。
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.089 秒)